The delivery of beva monoantigen affects the delivery of molybamine to improve the efficacy of treating recurring GBM.

The application of anti-icingant drug- beval monotherapy glioblastoma (GBM) has received widespread attention.
approved the treatment of beva monoantigen for GBM in December 2017, but it remains unclear how the drug regulates the delivery of chemotherapy drugs in the body.
Study by Elizabeth R. Gerstner of Harvard University Massachusetts General Hospital and others on the effects of beva monoantigens on tumor angiogenesis and tymoamine delivery in patients with relapsed GBM was published in the January 2020 issue of The Clinical Cancer Research.
the study, the researchers used 11C as a marker of tymoamine.
a patient line PET-MRI scan before, one day after use, and the third time before use of beval monoantigen.
, the GBM volume, vascular permeability Ktrans, cerebral blood flow perfusion pressure, and the standard absorption value of tymoamine in the tumor were calculated.
results were included in 12 patients and resulted in 23 PET-MRI scans.
most patients with fully fortified tumors, the absorption rate and vascular permeability decreased after the use of beva monoantigen, but the response to changes in perfusion pressure was variable (Figure 1).
When the low permeability of the tumor and the blood-brain barrier are not completely destroyed, increased perfusion pressure can increase the absorption rate of tymoamine;
1. MRI-PET scans using beva monoantitor and one month after use showed a decrease in tumor-reinforced volume, tymoamine absorption, cerebral blood flow perfusion pressure, and vascular permeability.
conclusion The authors believe that bevadan anti-treatment recurrence GBM can lead to a decrease in vascular permeability of tumors, thereby reducing tissue edema, but also affect the delivery efficiency of chemotherapy drug termoamine.
in some areas of the tumor, when permeability is low, increased perfusion pressure can improve the delivery of tymoamine.
results show that the application of beva monoantigen may be a double-edged sword, small dose of beval monoantitor helps to balance permeability and brain perfusion pressure, so that the treatment of combined modal phosphonamide to obtain better effects;
: The intellectual property rights of the content published by the Brain Medical Exchange's Outside Information, God's Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be licensed for use, the source must also be indicated.
welcome to forward and share.
.